2014 Immunotherapy Cancer Biotech Initial Public Offerings (IPOs)
In addition to Juno Therapeutics receiving FDA Orphan Drug Designation (ODD) for its lead product candidate JCAR015 for Acute Lymphoblastic Leukemia (ALL) last week, the company files a S-1 Form with the US Securities and Exchange Commission (SEC) Commission on November 17th. The S-1 proposes an Initial Public Offering (IPO) of its common stock raising up to $150 million. The company’s listing will be under the symbol “JUNO” on the NASDAQ Global Select Market. Morgan Stanley, J.P. Morgan and Goldman Sachs & Co are underwriting the IPO.
Per the S-1 Form, as of July 2014, JCAR015’s most recent data demonstrates, in an ongoing Phase I clinical trial, an amazing 91% complete remission rate in 22 evaluable adult patients with relapsed/refractory B cell ALL. Historical complete remission rates without JCAR015 in a similar population are less than 10%. JCAR015 Phase I trials are currently underway at Juno’s collaboration partner, Memorial Sloan-Kettering Cancer Center. The company plans on starting a Phase II trial in mid-2015 exploring JCAR015 in the same population that could support accelerated US regulatory approval.
By the end of 2015, Juno Therapeutics plans to start testing for at least 3 more drug candidates.
Other biotechnology IPOs in 2014 developing cancer immunotherapies:
• Kite Pharma (partnering with the US National Cancer Institute); Receives FDA ODD in March 2014 For Diffuse Large B-Cell Lymphoma (DLBCL) & EMA COMP positive opinion recommendation for ODD on November 17th
• Bellicum Pharmaceuticals (files 11/18/14 registration statement for proposed IPO with the US SEC to raise up to $115 million).
Copyright © 2012-2014, Orphan Druganaut Blog. All rights reserved.